NeurAxis is a fast-growing medtech company
Developing and commercializing neuromodulation therapies to address chronic and debilitating conditions, NeurAxis focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
NeurAxis is dedicated to advancing the science with its’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. We believe that superior science, evidence-based research, and building on our unparalleled body of clinical evidence is necessary for adoption by the medical and scientific community.
With one FDA indication in the market, additional clinical trials of PENFS in multiple pediatric conditions are underway, focused on unmet healthcare needs in children.
Established as a privately held company in 2012, NeurAxis went public in August 2023 (NYSEAMERICAN: NRXS).
Reimagine
Research
Innovate
Through innovation and research, we are reimagining the future of patient care so that all children, and the adults they grow up to be, can experience the lifelong benefits of being free from chronic pain. The company is evolving to also address the unmet health care needs of adults suffering from gastrointestinal issues.
The NeurAxis Mission
Improve lives by creating safe and effective treatments that mitigate debilitating pain and alleviate suffering among children. We aim to establish a new standard of care for patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS).
